Evidence map›Paper›PMID 37333134›Full record

ArticleResearch square2023

Preventing recurrence in Sonic Hedgehog Subgroup Medulloblastoma using the OLIG2 inhibitor CT-179.

Yuchen Li, Chaemin Lim, Taylor Dismuke, Daniel S Malawsky, Sho Oasa, Zara C Bruce, Carolin Offenhäuser, Ulrich Baumgartner, Rochelle C J D'Souza, Stacey L Edwards and 20 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 7 institutions in 6 countries.

Yuchen LiQIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Chaemin LimThese authors contributed equally.
Taylor DismukeThese authors contributed equally.
Daniel S MalawskyDepartment of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, 27599, USA.
Sho OasaDepartment of Clinical Neuroscience, Center for Molecular Medicine (CMM), Karolinska Institutet, 17176 Stockholm, Sweden.ORCID 0000-0003-3800-590X
Zara C BruceQIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Carolin OffenhäuserQIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.ORCID 0000-0003-2518-1779
Ulrich BaumgartnerQIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.ORCID 0000-0001-8170-0567
Rochelle C J D'SouzaQIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Stacey L EdwardsQIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.ORCID 0000-0001-7428-4139
Juliet D FrenchQIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.ORCID 0000-0002-9770-0198
Lucy S H OckQIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.ORCID 0000-0002-1680-3954
Sneha NairQIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Haran SivakumaranQIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.ORCID 0000-0002-4691-4989
Lachlan HarrisQIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Andrey P TikunovDepartment of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, 27599, USA.
Duhyeong HwangCenter for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA.
Coral Del Mar Alicea PaunetoDepartment of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, 27599, USA.
Mellissa MayburyChild Health Research Centre, The University of Queensland, Brisbane, QLD, 4101, Australia.
Timothy HassallThe University of Queensland, Brisbane, QLD, 4072, Australia.
Brandon WainwrightThe University of Queensland, Brisbane, QLD, 4072, Australia.
Santosh KesariCurtana Pharmaceuticals, Inc. Austin, TX 78756, United States.ORCID 0000-0003-3772-6000
Gregory SteinTelethon Kids Institute, Perth, WA, 6009, Australia.ORCID 0000-0002-3588-8834
Michael PiperThe University of Queensland, Brisbane, QLD, 4072, Australia.
Terrance G JohnsTelethon Kids Institute, Perth, WA, 6009, Australia.
Marina Sokolsky-PapkovCenter for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA.ORCID 0000-0002-3462-9013
Lars TereniusDepartment of Clinical Neuroscience, Center for Molecular Medicine (CMM), Karolinska Institutet, 17176 Stockholm, Sweden.
Vladana VukojevićDepartment of Clinical Neuroscience, Center for Molecular Medicine (CMM), Karolinska Institutet, 17176 Stockholm, Sweden.ORCID 0000-0003-0873-5653
Timothy R GershonDepartment of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, 27599, USA.ORCID 0000-0001-7034-6400
Bryan W DayQIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
University of North Carolina at Chapel Hill · USQIMR Berghofer Medical Research Institute · AUThe University of Queensland · AUKarolinska Institutet · SEQueensland University of Technology · AUThe Kids Research Institute Australia · AUCancer Institute (WIA) · IN

Funding

Bcl-xL-regulated apoptosis in cerebellar development and medulloblastoma treatmentR01NS102627 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GERSHON, TIMOTHY · 2018 to 2022
$1.8M
Defining the crucial role of MAGOH in cerebellar development and the potential for targeting the EJC in medulloblastoma treatmentR01NS106227 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GERSHON, TIMOTHY · 2018 to 2023
$1.7M
Glycolytic regulation of cerebellar development and medulloblastoma tumorigenesisR01NS088219 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GERSHON, TIMOTHY · 2015 to 2019
$1.6M
Improving CDK 4/6 inhibition in the treatment of medulloblastomaF31NS120459 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DISMUKE, TAYLOR YVETTE · 2020 to 2022
$59k
NINDS NIH HHS F31 NS120459NINDS NIH HHS R01 NS088219NINDS NIH HHS R01 NS102627NINDS NIH HHS R01 NS106227
6 · The paper itself

Abstract

Recurrence is the primary life-threatening complication for medulloblastoma (MB). In Sonic Hedgehog (SHH)-subgroup MB, OLIG2-expressing tumor stem cells drive recurrence. We investigated the anti-tumor potential of the small-molecule OLIG2 inhibitor CT-179, using SHH-MB patient-derived organoids, patient-derived xenograft (PDX) tumors and mice genetically-engineered to develop SHH-MB. CT-179 disrupted OLIG2 dimerization, DNA binding and phosphorylation and altered tumor cell cycle kinetics

Indexed as

CT-179MedulloblastomaOLIG2pre-clinical

Identifiers

PMID37333134
PMCPMC10275055
OpenAlexW4380085193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.